UroGen Pharma

Company snapshot

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be ap

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for UroGen Pharma. Not investment advice.

• What is UroGen Pharma?

  EuroGen Pharmaceuticals is a pharma organization headquartered in GB. Primary therapeutic focus areas include Spinal Cord Injury, Neurological; Disorder, Nervous System. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from publ

• Is UroGen Pharma publicly traded?

  UroGen Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does UroGen Pharma develop or market?

  We link 5 drug profile(s) where UroGen Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/eurogen-pharmaceuticals-ltd#company-drugs.

• What are the latest developments for UroGen Pharma?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does UroGen Pharma focus on?

  UroGen Pharma focuses on Spinal Cord Injury, Neurological; Disorder, Nervous System based on our analysis of their pipeline programs and drug development activities.